An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT07084584 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions

DRUG: GB3226

Sponsor

Galecto Biotech AB